These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24256081)

  • 1. Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins.
    Xia A; Stempak JM; Grist J; Bressler B; Silverberg MS; Bach H
    Scand J Gastroenterol; 2014 Feb; 49(2):157-63. PubMed ID: 24256081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of Mycobacterium avium subsp. paratuberculosis proteins in Crohn's disease patients.
    Bach H; Ko HH; Raizman EA; Attarian R; Cho B; Biet F; Enns R; Bressler B
    Scand J Gastroenterol; 2011 Jan; 46(1):30-9. PubMed ID: 20735153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of PtpA secreted during Mycobacterium avium ssp. paratuberculosis infection in cattle.
    Bach E; Raizman EA; Vanderwal R; Soto P; Chaffer M; Keefe G; Pogranichniy R; Bach H
    Vet Immunol Immunopathol; 2018 Apr; 198():1-5. PubMed ID: 29571512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease?
    Polymeros D; Bogdanos DP; Day R; Arioli D; Vergani D; Forbes A
    Gastroenterology; 2006 Jul; 131(1):85-96. PubMed ID: 16831593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophages from IBD patients exhibit defective tumour necrosis factor-α secretion but otherwise normal or augmented pro-inflammatory responses to infection.
    Campos N; Magro F; Castro AR; Cabral J; Rodrigues P; Silva R; Appelberg R; Rodrigues S; Lopes S; Macedo G; Sarmento A
    Immunobiology; 2011 Aug; 216(8):961-70. PubMed ID: 21269730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the interaction between NOD-2 status and serological response to Mycobacterium paratuberculosis in cases of inflammatory bowel disease.
    Bernstein CN; Wang MH; Sargent M; Brant SR; Collins MT
    J Clin Microbiol; 2007 Mar; 45(3):968-71. PubMed ID: 17251406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific antibodies against recombinant protein of insertion element 900 of Mycobacterium avium subspecies paratuberculosis in Japanese patients with Crohn's disease.
    Nakase H; Nishio A; Tamaki H; Matsuura M; Asada M; Chiba T; Okazaki K
    Inflamm Bowel Dis; 2006 Jan; 12(1):62-9. PubMed ID: 16374261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of seroreactive proteins in the culture filtrate antigen of Mycobacterium avium ssp. paratuberculosis human isolates to sera from Crohn's disease patients.
    Shin AR; Kim HJ; Cho SN; Collins MT; Manning EJ; Naser SA; Shin SJ
    FEMS Immunol Med Microbiol; 2010 Feb; 58(1):128-37. PubMed ID: 19878316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Crohn's disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins.
    Bach H; Rosenfeld G; Bressler B
    J Crohns Colitis; 2012 Jun; 6(5):628-9. PubMed ID: 22398081
    [No Abstract]   [Full Text] [Related]  

  • 11. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective Th2 pattern of cytokine secretion in Mycobacterium avium subsp. paratuberculosis infected Crohn's disease.
    Ren Z; Turton J; Borody T; Pang G; Clancy R
    J Gastroenterol Hepatol; 2008 Feb; 23(2):310-4. PubMed ID: 18289359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum antibodies to Mycobacterium avium subspecies paratuberculosis combined with anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients: prevalence and diagnostic role.
    Biet F; Gendt L; Anton E; Ballot E; Hugot JP; Johanet C
    Dig Dis Sci; 2011 Jun; 56(6):1794-800. PubMed ID: 21221802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Humoral response to mycobacteria in patients with Crohn disease].
    Morgante P; López B; Barrera L; Ritacco V; de Kantor IN
    Medicina (B Aires); 1994; 54(2):97-102. PubMed ID: 7997145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Mycobacterium avium subsp. paratuberculosis (MAP)-specific IS900 DNA and antibodies against MAP peptides and lysate in the blood of Crohn's disease patients.
    Di Sabatino A; Paccagnini D; Vidali F; Rosu V; Biancheri P; Cossu A; Zanetti S; Corazza GR; Sechi LA
    Inflamm Bowel Dis; 2011 May; 17(5):1254-5. PubMed ID: 20815038
    [No Abstract]   [Full Text] [Related]  

  • 17. Elevated antibody responses in patients with Crohn's disease against a 14-kDa secreted protein purified from Mycobacterium avium subsp. paratuberculosis.
    Olsen I; Wiker HG; Johnson E; Langeggen H; Reitan LJ
    Scand J Immunol; 2001 Feb; 53(2):198-203. PubMed ID: 11169225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum bacterial toxins are related to the progression of inflammatory bowel disease.
    Qiu H; Sun X; Sun M; He C; Li Z; Liu Z
    Scand J Gastroenterol; 2014 Jul; 49(7):826-33. PubMed ID: 24853095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium avium subsp. Paratuberculosis (MAP) as a modifying factor in Crohn's disease.
    Sibartie S; Scully P; Keohane J; O'Neill S; O'Mahony J; O'Hanlon D; Kirwan WO; O'Mahony L; Shanahan F
    Inflamm Bowel Dis; 2010 Feb; 16(2):296-304. PubMed ID: 19824071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.